Last updated: September 15, 2026
Metreleptin, marketed as Myalept in the United States and Myalepta in Europe, is a specialized leptin-replacement biologic for patients with severe lipodystrophy. Its commercial profile is defined by a small addressable population, high annual treatment value, limited therapeutic substitution, and significant reimbursement and distribution controls. Chiesi now owns the product following its 2023 acquisition of Amryt Pharma, which acquired the relevant Aegerion assets in 2019.
The product’s principal commercial protection is no longer a conventional composition-of-matter patent. U.S. orphan-drug exclusivity expired in 2021, while the 12-year reference-product exclusivity period under the Biologics Price Competition and Innovation Act is expected to run into 2026. Actual near-term erosion risk remains limited because of the small patient pool, complex diagnosis, specialized prescribing requirements, and the absence of an established biosimilar competitor.
What is metreleptin and which patients use it?
Metreleptin is a recombinant analog of human leptin. It replaces deficient leptin in patients with congenital or acquired generalized lipodystrophy, a group of disorders characterized by abnormal loss of adipose tissue, severe insulin resistance, hypertriglyceridemia, and ectopic fat accumulation.
In the United States, Myalept is approved as an adjunct to diet for replacement therapy to treat complications associated with leptin deficiency in patients with congenital or acquired generalized lipodystrophy. The FDA did not approve it for obesity or for patients with ordinary metabolic disease. The product carries a boxed warning concerning anti-metreleptin antibodies with neutralizing activity and the risk of lymphoma (FDA, 2024a).
The European indication is broader. Myalepta is authorized for the treatment of leptin deficiency associated with lipodystrophy in adults and children aged two years and older, including generalized and partial lipodystrophy when standard treatments have failed to achieve adequate metabolic control (European Medicines Agency [EMA], 2024).
What are the principal product specifications?
| Attribute |
United States |
European Union |
| Brand |
Myalept |
Myalepta |
| Active ingredient |
Metreleptin |
Metreleptin |
| Product type |
Recombinant protein biologic |
Recombinant protein biologic |
| Route |
Subcutaneous injection |
Subcutaneous injection |
| Initial approval |
February 2014 |
July 2018 |
| Lead company |
Chiesi USA |
Chiesi Farmaceutici |
| Main indication |
Generalized lipodystrophy |
Generalized and selected partial lipodystrophy |
| Distribution |
Restricted specialty distribution and REMS controls |
National reimbursement and specialist channels |
| Direct approved replacement competitor |
None |
None |
How large is the metreleptin market?
The addressable population is very small, but the treatment value per patient is high. Generalized lipodystrophy is an ultra-rare condition. Published prevalence estimates vary because diagnosis is incomplete and national registries use different case definitions. The U.S. commercial opportunity is therefore measured in a small number of treated patients rather than in millions of prescriptions.
The market has three structural characteristics:
- High treatment persistence. Patients who respond to metreleptin generally require chronic therapy.
- Limited therapeutic substitution. Insulin, triglyceride-lowering drugs, dietary intervention, and diabetes therapies manage complications but do not replace leptin.
- High reimbursement sensitivity. Payers frequently require confirmation of the diagnosis, specialist prescribing, prior authorization, and evidence of metabolic complications.
The U.S. market is economically more concentrated than the European market because the U.S. label is limited to generalized lipodystrophy, while the European label includes certain patients with partial lipodystrophy. The European commercial opportunity is broader but fragmented across country-level reimbursement decisions.
What is the financial trajectory for metreleptin?
Chiesi does not publicly report Myalept or Myalepta revenue as a separate line item in its consolidated disclosures. The most useful financial data comes from Amryt Pharma before its acquisition by Chiesi.
Amryt reported total revenue of approximately $217.7 million in 2021 and approximately $301.9 million in 2022. Those figures represented the company’s full commercial portfolio, including Myalept, Mycapssa, Juxtapid, and other rare-disease products. Myalept was a material contributor, but Amryt did not provide a consistently detailed, audited product-level revenue series that isolates metreleptin sales for all reporting periods (Amryt Pharma plc, 2023).
How did ownership affect the product’s financial trajectory?
| Period |
Owner or commercial sponsor |
Financial implication |
| 2014-2019 |
Aegerion Pharmaceuticals |
U.S. commercialization following FDA approval |
| 2019-2023 |
Amryt Pharma |
Integration into a broader rare-disease portfolio |
| 2023 onward |
Chiesi Group |
Integration into a larger specialty-care and rare-disease platform |
| 2022 benchmark |
Amryt |
Approximately $301.9 million total company revenue |
| Current reporting issue |
Chiesi |
Product-level Myalept revenue is not separately disclosed |
The Amryt acquisition increased the strategic value of metreleptin beyond its standalone revenue. The product added a chronic, orphan biologic with specialist prescribers, a concentrated patient-support infrastructure, and limited direct competition. Chiesi paid approximately $1.25 billion to acquire Amryt, subject to the transaction terms and adjustments disclosed at the time. The purchase price reflected the full portfolio rather than a separately disclosed value for Myalept (Chiesi Farmaceutici, 2023).
What drives revenue growth?
Revenue growth depends primarily on four variables:
- New patient diagnosis and referral into specialist centers.
- Reimbursement approval and continuation rates.
- Patient retention and dose intensity.
- Geographic expansion, especially in European partial-lipodystrophy patients.
Price increases can affect reported revenue, but pricing is constrained by payer scrutiny and the small number of patients exposed to treatment. The most durable growth opportunity is diagnosis expansion rather than mass-market volume.
When does metreleptin lose exclusivity?
The relevant U.S. exclusivity periods are separate and should not be treated as a single expiration date.
| Protection |
Key date or status |
Commercial significance |
| FDA approval |
February 24, 2014 |
Established the U.S. reference product |
| Orphan-drug exclusivity |
Approximately seven years from approval |
Expired in 2021 |
| BPCIA reference-product exclusivity |
Twelve years from first licensure |
Expected to extend into 2026 |
| Core leptin composition patents |
Generally historical and expired or near-expired |
Limited current blocking value |
| Formulation and manufacturing know-how |
Potentially continuing |
May raise development and quality barriers |
| REMS and restricted distribution |
Continuing regulatory controls |
Increases operational barriers for entrants |
The 12-year reference-product exclusivity period is not the same as patent protection. It limits FDA approval of a biosimilar relying on the reference product during the statutory period, subject to the operation of the BPCIA. It does not prevent an independent biologic application based on a different development strategy.
A biosimilar applicant may have been able to submit an application after four years from first licensure, but approval could not take effect before the end of the 12-year reference-product exclusivity period. A practical U.S. launch risk therefore begins after the expected 2026 reference-product exclusivity endpoint, subject to litigation, patent listing, interchangeability issues, and FDA review.
What patents protect metreleptin?
The original intellectual-property position centered on leptin, recombinant production, and related therapeutic uses. Early leptin composition and use patents were filed in the 1990s and generally have limited remaining term because U.S. patent protection normally runs 20 years from the earliest effective nonprovisional filing date.
The commercial protection that matters now is more likely to arise from:
- Product-specific formulation claims.
- Stable liquid or lyophilized dosage forms.
- Protein recovery and purification processes.
- Manufacturing controls and comparability data.
- Device or delivery-system claims.
- Method-of-use claims directed to defined lipodystrophy populations.
- Regulatory exclusivity and patient-support infrastructure.
The Orange Book is not the primary competitive reference for a biologic. Myalept is licensed under a biologics license application, and the relevant U.S. pathway is generally a 351(a) full biologics application or a 351(k) biosimilar application under the Public Health Service Act. Drug establishments and patent listings can still affect competition, but the Orange Book does not provide the same complete market map for biologics that it provides for small-molecule drugs (FDA, 2024b).
Are formulation patents important for Myalept?
Formulation and manufacturing patents can be more important than the original leptin patents because recombinant proteins are sensitive to aggregation, degradation, impurities, container interaction, and batch-to-batch comparability.
A later entrant would need to demonstrate a highly similar product or independently establish safety, efficacy, immunogenicity, and manufacturing consistency. Even if a biosimilar avoids an enforceable patent barrier, development costs and the need to recruit or access a very small patient population can delay entry.
Public commercial analysis should distinguish among:
- Patents listed for the reference product.
- Patents asserted in BPCIA litigation.
- Patents covering production methods rather than the product itself.
- Unpublished manufacturing know-how that does not appear in a public patent database.
Has metreleptin faced Paragraph IV challenges or biosimilar litigation?
There is no established public record, through June 2024, of a successful Paragraph IV generic challenge directed at Myalept. Paragraph IV is primarily a Hatch-Waxman mechanism for small-molecule drugs. Metreleptin is a biologic, so a potential competitor would normally proceed through the BPCIA biosimilar framework rather than a conventional abbreviated new drug application.
No marketed U.S. biosimilar to metreleptin had been identified through June 2024. The absence of a biosimilar does not mean that the product has indefinite exclusivity. It reflects the combination of a small market, specialized clinical use, manufacturing complexity, uncertain payer discounts, and the limited economic incentive to fund a stand-alone development program.
What is the FDA regulatory status of Myalept?
Myalept has full U.S. approval for generalized lipodystrophy, but its use is tightly controlled.
The FDA’s principal regulatory features are:
- Approval under BLA 125546.
- Orphan-drug designation.
- Boxed warning for anti-metreleptin antibodies with neutralizing activity and lymphoma risk.
- REMS requirements related to serious risks and controlled distribution.
- Restricted prescribing and dispensing arrangements.
- No approval for ordinary obesity or general insulin resistance.
The REMS program adds friction for both physicians and patients. It also helps preserve a specialized commercial channel that a future competitor would need to replicate.
What generic or biosimilar launch risks exist?
Near-term risk: low to moderate
Before the expected end of BPCIA reference-product exclusivity in 2026, a competing 351(k) product faces a regulatory timing barrier. Patent or exclusivity disputes could extend the practical delay.
Medium-term risk: moderate
After 2026, the principal risks are:
- A biosimilar sponsor entering with a lower price.
- Payer-mandated substitution or preferred formulary placement.
- A competitor targeting generalized lipodystrophy first and later seeking broader labeling.
- Independent biologic development that avoids reliance on Myalept’s data package.
- Greater use of GLP-1 drugs, insulin sensitizers, and triglyceride therapies in partial-lipodystrophy populations.
Long-term risk: still constrained by market structure
Even with biosimilar entry, price erosion may be less severe than in large biologic markets. The patient population is too small to support many competitors, and physicians may prioritize continuity of response and established immunogenicity data. The risk is more likely to involve selective payer discounts and account-level switching than rapid broad substitution.
How does metreleptin compare with alternative treatments?
| Treatment category |
Role in lipodystrophy |
Replaces leptin deficiency? |
Competitive threat to metreleptin |
| Metreleptin |
Leptin replacement |
Yes |
Reference therapy |
| Insulin and insulin sensitizers |
Glycemic control |
No |
Low to moderate |
| Fibrates and omega-3 therapies |
Hypertriglyceridemia |
No |
Low |
| Statins |
Cardiovascular risk management |
No |
Low |
| GLP-1 receptor agonists |
Weight and glycemic management |
No |
Moderate in selected partial cases |
| Dietary therapy |
Metabolic support |
No |
Complementary |
| Bariatric or metabolic procedures |
Selected metabolic complications |
No |
Limited and patient-specific |
The strongest competitive pressure is not a direct replacement. It is payer and physician use of broader metabolic therapies in patients who do not meet the narrowest criteria for metreleptin or who have partial lipodystrophy.
What licensing and commercial deals affect metreleptin?
The major transaction history is ownership-related rather than a separate licensing deal:
- Aegerion commercialized Myalept after FDA approval.
- Amryt acquired Aegerion and its products in 2019.
- Chiesi agreed to acquire Amryt in 2023 for approximately $1.25 billion.
The Chiesi transaction transferred commercial rights, regulatory infrastructure, patient-support operations, and the wider rare-disease portfolio. It also placed Myalept within a company with greater international reach and a broader specialty-care sales organization.
What is the geographic coverage of metreleptin?
The product has the greatest commercial relevance in the United States and Europe.
- United States: Generalized lipodystrophy indication; specialist prescribing; REMS and restricted distribution.
- European Union: Generalized and selected partial lipodystrophy; country-specific health technology assessment and reimbursement.
- Other markets: Availability depends on local registration, named-patient access, national reimbursement, and Chiesi’s commercial strategy.
European access is likely to vary substantially by country. A centralized marketing authorization does not guarantee uniform reimbursement or unrestricted use.
How strong is the metreleptin patent and commercial estate?
The estate is commercially stronger than the remaining core patent term suggests, but weaker than a recently launched biologic with active composition patents.
| Protection category |
Assessment |
| Core molecule patent |
Weak current blocking value because of age |
| Regulatory exclusivity |
Meaningful through the expected 2026 reference-product period |
| Orphan exclusivity |
Expired in the United States |
| Manufacturing know-how |
Potentially meaningful |
| REMS and distribution controls |
High operational barrier |
| Clinical experience |
Strong relative advantage |
| Patient identification |
Important commercial asset |
| Direct competition |
Limited through June 2024 |
| Biosimilar vulnerability |
Increasing after 2026 |
The product’s defensibility is therefore based on regulatory history, clinical familiarity, manufacturing complexity, and channel control rather than on a long remaining patent runway.
Key Takeaways
- Metreleptin is the only approved leptin-replacement therapy for lipodystrophy in the United States and Europe.
- U.S. approval is limited to generalized lipodystrophy; the European label includes selected partial-lipodystrophy patients.
- Chiesi owns Myalept following its acquisition of Amryt in 2023.
- Amryt’s total revenue reached approximately $301.9 million in 2022, but standalone Myalept revenue was not separately reported in a consistently detailed public series.
- U.S. orphan-drug exclusivity expired in 2021.
- BPCIA reference-product exclusivity is expected to extend into 2026.
- No marketed U.S. metreleptin biosimilar or major public Paragraph IV challenge was identified through June 2024.
- Near-term erosion risk is limited by the small patient population, complex manufacturing, REMS obligations, and specialist reimbursement.
- The principal post-2026 risk is selective biosimilar discounting rather than immediate mass-market substitution.
- Revenue growth depends more on diagnosis, reimbursement, and geographic expansion than on broad prescription volume.
FAQs
What is the annual cost of Myalept treatment?
The annual cost varies by dose, patient weight, payer discounts, and U.S. or international pricing. Because dosing is weight-based and chronic, gross annual treatment value can reach the high six figures for some patients. Net prices are not publicly disclosed consistently.
Is Myalept approved for obesity?
No. The FDA approved Myalept for complications associated with leptin deficiency in congenital or acquired generalized lipodystrophy. It is not approved for common obesity.
Can a generic company make a generic version of metreleptin?
A conventional small-molecule generic pathway is generally not appropriate. A competitor would more likely pursue a 351(k) biosimilar application or a full 351(a) biologics application.
Does Myalept have patent protection after 2026?
Potentially. The end of reference-product exclusivity does not automatically invalidate every patent. Any surviving formulation, manufacturing, device, or method-of-use claims would need to be assessed separately.
What is the main investment risk for metreleptin revenue?
The principal risk is concentrated-payer pressure after biosimilar entry or expanded use of alternative metabolic therapies in partial-lipodystrophy patients. The small market limits the number of likely entrants but also concentrates revenue in a narrow specialist and reimbursement base.
References
Amryt Pharma plc. (2023). Annual report and accounts 2022.
Chiesi Farmaceutici. (2023). Chiesi Farmaceutici completes acquisition of Amryt Pharma plc.
European Medicines Agency. (2024). Myalepta: EPAR - product information.
U.S. Food and Drug Administration. (2024a). Myalept prescribing information.
U.S. Food and Drug Administration. (2024b). Purple Book: Database of licensed biological products.
